sarepta

This Controversial Biotech May Yet Defy Its Skeptics

Sarepta stock spiked 14% thanks to its experimental muscular dystrophy drug...

Sarepta stock spiked 14% thanks to its experimental muscular dystrophy drug.

Drug Giant Sanofi May Be Getting Ready to Buy Up This Rare Disease Company

Sarepta Therapeutics shares are up today on the speculation.

Sarepta Therapeutics shares are up today on the speculation.

Gilead Just Paid $125 Million to Nab a Big Market Advantage

The biotech giant can now speed up the drug review process.

The biotech giant can now speed up the drug review process.

Drug Company Hits Pause on Launching an $89,000 Muscular Dystrophy Drug After Backlash

After a huge backlash and a Congressional inquiry.

After a huge backlash and a Congressional inquiry.

This Pharma Company Is Selling a Decades-old Drug to Treat Muscular Dystrophy for $89,000

Seventy times higher than what it's listed for overseas

Seventy times higher than what it's listed for overseas

Insurers are Rebelling Against the FDA's Most Controversial 2016 Drug Approval

Sarepta's drug for a devastating rare disease is getting a lot of scrutiny.

Sarepta's drug for a devastating rare disease is getting a lot of scrutiny.